Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Rhapsido (remibrutinib by Quarter
Rhapsido (remibrutinib — oral BTK inhibitor for chronic spontaneous urticaria CSU, launch Q4 2025) ($M)
Novartis Rhapsido (remibrutinib: $101M in Q3 2026.
Latest, Q3 2026
101
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
4
Documents cited below
Where the Q3 2026 figure comes from
“|| Rhapsido | 101 | nm | nm”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rhapsido (remibrutinib — oral BTK inhibitor for chronic spontaneous urticaria CSU, launch Q4 2025) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 101 | – | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 64 | – | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 37 | – | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 19 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
Cite this data
StockData. (2026). Novartis Rhapsido (remibrutinib ($M), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-rhapsido
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.